447 related articles for article (PubMed ID: 25328138)
1. Topoisomerase IIα in chromosome instability and personalized cancer therapy.
Chen T; Sun Y; Ji P; Kopetz S; Zhang W
Oncogene; 2015 Jul; 34(31):4019-31. PubMed ID: 25328138
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
Bower JJ; Karaca GF; Zhou Y; Simpson DA; Cordeiro-Stone M; Kaufmann WK
Oncogene; 2010 Aug; 29(34):4787-99. PubMed ID: 20562910
[TBL] [Abstract][Full Text] [Related]
3. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
4. Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/- mutants.
Sapetto-Rebow B; McLoughlin SC; O'Shea LC; O'Leary O; Willer JR; Alvarez Y; Collery R; O'Sullivan J; Van Eeden F; Hensey C; Kennedy BN
BMC Dev Biol; 2011 Nov; 11():71. PubMed ID: 22111588
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
Järvinen TA; Liu ET
Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
[TBL] [Abstract][Full Text] [Related]
6. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
Gardner L; Malik R; Shimizu Y; Mullins N; ElShamy WM
Breast Cancer Res; 2011 May; 13(3):R53. PubMed ID: 21595939
[TBL] [Abstract][Full Text] [Related]
7. BAF complexes facilitate decatenation of DNA by topoisomerase IIα.
Dykhuizen EC; Hargreaves DC; Miller EL; Cui K; Korshunov A; Kool M; Pfister S; Cho YJ; Zhao K; Crabtree GR
Nature; 2013 May; 497(7451):624-7. PubMed ID: 23698369
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
9. RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation.
Guturi KKN; Bohgaki M; Bohgaki T; Srikumar T; Ng D; Kumareswaran R; El Ghamrasni S; Jeon J; Patel P; Eldin MS; Bristow R; Cheung P; Stewart GS; Raught B; Hakem A; Hakem R
Nat Commun; 2016 Aug; 7():12638. PubMed ID: 27558965
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
11. Histone H2A phosphorylation recruits topoisomerase IIα to centromeres to safeguard genomic stability.
Zhang M; Liang C; Chen Q; Yan H; Xu J; Zhao H; Yuan X; Liu J; Lin S; Lu W; Wang F
EMBO J; 2020 Feb; 39(3):e101863. PubMed ID: 31769059
[TBL] [Abstract][Full Text] [Related]
12. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
[TBL] [Abstract][Full Text] [Related]
13. Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells.
Belluti S; Basile V; Benatti P; Ferrari E; Marverti G; Imbriano C
Cell Death Dis; 2013 Aug; 4(8):e756. PubMed ID: 23928695
[TBL] [Abstract][Full Text] [Related]
14. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
Coss A; Tosetto M; Fox EJ; Sapetto-Rebow B; Gorman S; Kennedy BN; Lloyd AT; Hyland JM; O'Donoghue DP; Sheahan K; Leahy DT; Mulcahy HE; O'Sullivan JN
Cancer Lett; 2009 Apr; 276(2):228-38. PubMed ID: 19111388
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.
Järvinen TA; Liu ET
Cytopathology; 2003 Dec; 14(6):309-13. PubMed ID: 14632727
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer.
Järvinen TA; Liu ET
Comb Chem High Throughput Screen; 2003 Aug; 6(5):455-70. PubMed ID: 12871052
[TBL] [Abstract][Full Text] [Related]
17. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.
Wray J; Williamson EA; Royce M; Shaheen M; Beck BD; Lee SH; Nickoloff JA; Hromas R
PLoS One; 2009; 4(4):e5323. PubMed ID: 19390626
[TBL] [Abstract][Full Text] [Related]
18. A chromatin remodeling complex regulates topoisomerase IIα function.
Cancer Discov; 2013 Jul; 3(7):OF33. PubMed ID: 23847378
[TBL] [Abstract][Full Text] [Related]
19. Sister chromatid decatenation: bridging the gaps in our knowledge.
Broderick R; Niedzwiedz W
Cell Cycle; 2015; 14(19):3040-4. PubMed ID: 26266709
[TBL] [Abstract][Full Text] [Related]
20. Structural organization of the human TOP2A and TOP2B genes.
Lang AJ; Mirski SE; Cummings HJ; Yu Q; Gerlach JH; Cole SP
Gene; 1998 Oct; 221(2):255-66. PubMed ID: 9795238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
